| Names | |
|---|---|
| Preferred IUPAC name | 2-acetyloxybenzoic acid |
| Other names | Acetylsalicylic Acid ASA Bayer Ecotrin Bufferin |
| Pronunciation | /ˈæs.pər.ɪn ˈtæb.lət/ |
| Identifiers | |
| CAS Number | 50-78-2 |
| Beilstein Reference | 6068 |
| ChEBI | CHEBI:15365 |
| ChEMBL | CHEMBL25 |
| ChemSpider | 2157 |
| DrugBank | DB00945 |
| ECHA InfoCard | 03f872c0-3c18-420f-9c8d-aee1d02ac0c7 |
| EC Number | 337 |
| Gmelin Reference | Aspirin Tablet: "2052 |
| KEGG | D00109 |
| MeSH | D001241 |
| PubChem CID | 2244 |
| RTECS number | AU8405000 |
| UNII | O414PZ4LPZ |
| UN number | UN1851 |
| Properties | |
| Chemical formula | C9H8O4 |
| Molar mass | 180.16 g/mol |
| Appearance | White, round, biconvex, uncoated tablet |
| Odor | odorless |
| Density | 1.4 g/cm3 |
| Solubility in water | Slightly soluble |
| log P | 1.19 |
| Acidity (pKa) | 3.5 |
| Basicity (pKb) | 15.5 |
| Magnetic susceptibility (χ) | Diamagnetic |
| Refractive index (nD) | 1.616 |
| Dipole moment | 1.51 D |
| Thermochemistry | |
| Std molar entropy (S⦵298) | 165 J·mol⁻¹·K⁻¹ |
| Std enthalpy of formation (ΔfH⦵298) | No data |
| Std enthalpy of combustion (ΔcH⦵298) | -3166 kJ/mol |
| Pharmacology | |
| ATC code | B01AC06 |
| Hazards | |
| Main hazards | May cause eye, skin, and respiratory tract irritation. Harmful if swallowed. |
| GHS labelling | GHS07 |
| Pictograms | expiration-date, keep-dry, keep-away-from-children, do-not-freeze, do-not-crush |
| Signal word | Warning |
| Hazard statements | No hazard statements. |
| Precautionary statements | Keep out of reach of children. In case of overdose, get medical help or contact a Poison Control Center right away. |
| NFPA 704 (fire diamond) | 2-1-0 |
| Lethal dose or concentration | LD50 (oral, rat): 200 mg/kg |
| LD50 (median dose) | LD50 (median dose): 200 mg/kg (oral, rat) |
| NIOSH | MN3500000 |
| PEL (Permissible) | 15 mg/m³ |
| REL (Recommended) | 325 mg |
| Related compounds | |
| Related compounds | Salicylic acid Acetaminophen Ibuprofen Naproxen Methyl salicylate |
| Property | Description / Commentary |
|---|---|
| Product Name | Aspirin Tablet |
| IUPAC Name | 2-Acetoxybenzoic acid (active ingredient: acetylsalicylic acid) |
| Chemical Formula | C9H8O4 (for active ingredient) |
| Synonyms & Trade Names | Aspirin, Acetylsalicylic Acid Tablet, ASA Tablet; common trade names vary by region and customer specification; tablets may include excipients as defined by client and regulatory requirements. |
| HS Code & Customs Classification | The World Customs Organization references 3004.90 for finished aspirin preparations. Actual code assignment responds to formulation (pure vs. formulated), tablet size, and regional customs policy. Bulk acetylsalicylic acid may fall under 2918.22. Classification must follow local code assignment practice for finished medicinal dosage forms and excipients present. |
Producing aspirin in tablet form involves selection of pharmaceutical-grade acetylsalicylic acid and compliance with pharmacopeia monograph (e.g., USP, EP, JP), which dictates not just active content but impurity landscape, moisture control, and tablet disintegration kinetics. For contract manufacturing or own-brand production, excipients such as microcrystalline cellulose, starch, or lactose can be varied based on compressibility, dissolution rate, and patient requirements.
Impurity profile varies with the synthetic route: Kolbe-Schmitt or direct acetylation methods introduce specific trace by-products, including salicylic acid and acetic acid residues. Routine in-process control screens for hydrolysis products, particle size distribution, and blend uniformity before compression to limit batch-to-batch variability. Excipients must not interact with the active ingredient. Stability studies drive the choice of film coating and packaging, especially in markets with varying humidity and temperature exposure.
Finished aspirin tablets undergo quality release only after meeting dissolution, friability, and uniformity requirements. Specifications for these attributes reflect customer, regulatory, and grade-level differences. Contractual QC protocols may include third-party reference standard testing for high-value pharmaceutical clients. For export documentation, HS code assignment typically relies on confirmation of product finish, excipient load, and intended end use recognized by customs authorities. Assembly of supporting documentation is always calibrated for the precise formulation and region to avoid customs or supply chain discrepancies.
Aspirin tablets present as compressed, solid units. White to off-white coloration is standard. Tablets are odorless. The tactile character enables consistent mechanical processing during tableting. Melting point of the active ingredient, acetylsalicylic acid, typically falls within 134–136 °C, with variability linked to purity and particle size. Tablets as final products show no boiling point, flash point, or vapor pressure. Density and friability vary with excipient choice and compression force, parameters set by the tablet grade and intended breaking strength.
Aspirin’s stability requires attention to temperature and humidity. In solid form, the compound is susceptible to hydrolysis under moist or alkaline conditions, generating salicylic acid and acetic acid. Oxidative degradation remains minimal if protected from air and excessive temperature. For pharmaceutical processing, storage handling needs tight moisture control to limit breakdown and odor generation.
Aspirin displays low water solubility, enhanced in alkaline and certain organic solvent environments. Solubility profile influences granulation, dissolution rate, and final bioavailability. Solution preparation for assay testing or analytical methods utilizes buffer systems to ensure complete dissolution of the active component without generating degradation products.
| Parameter | Pharmaceutical Grade | Technical/Industrial Grade |
|---|---|---|
| Assay (Acetylsalicylic acid) | Defined according to pharmacopoeial monograph | Defined by application and local standards |
| Loss on Drying | Grade-specific limits | Process-dependent |
| Heavy Metals | Pharmacopoeial maximums | Application-dependent |
Profile includes salicylic acid, residual solvents, and organic acidic degradants. Generation and magnitude depend heavily on synthesis route and raw material selection. Impurity maxima adhere to internal and pharmacopoeial quality limits set for each product grade. Rigorous routine monitoring with chromatographic and titrimetric techniques helps maintain batch consistency.
Product is assessed according to compendial or customer-driven test protocols: assay, related substances, disintegration, dissolution, microbial load. Primary standards are set by USP, EP, and JP, supplemented by in-house validated methods customized to production reality and downstream requirements.
Manufacturing starts from salicylic acid and acetic anhydride. Sourcing prioritizes high-purity reagents, with supplier qualification audits targeting traceability, contaminant history, and batch-to-batch reproducibility. For tablets, excipients—lactose, starch, binders—must conform to pharmaceutical requirements and match product design for dissolution or taste-masking.
Production rests on an acetylation reaction: salicylic acid acetylated by acetic anhydride, yielding acetylsalicylic acid plus acetic acid as byproduct. Reaction proceeds under acidic catalysis and controlled temperature conditions to balance yield and purity. Process water quality and reaction time influence hydrolytic impurity formation, so operators maintain precise control.
Critical control points include moisture exclusion, reaction temperature, and agitation. Purification includes recrystallization and, for pharmaceutical grade, repeated washing or additional filtration to remove acetic acid and colored impurities. Tablet manufacture layers in additional steps—milling, blending, granulation, compression—each validated for uniform content and mechanical integrity.
Release criteria stem from in-line analytical controls and finished product testing. Analytical control covers assay, impurities, mechanical properties, and microbial enumeration. Batch release demands conformity to customer specification and pharmacopoeial standards, supported by full documentation and traceability.
Aspirin undergoes hydrolysis, particularly under alkaline or moist conditions, producing salicylic acid and acetic acid. For industrial and formulation chemists, awareness of this pathway is essential in any solution or blend requiring extended storage or aqueous processing.
Large-scale synthesis typically uses an acid catalyst (e.g., sulfuric acid or phosphoric acid), with careful monitoring of reaction temperature to optimize yield. Solvent choice impacts product isolation and purification efficiency; purified water and specific organic solvents support final crystallization.
Acetylsalicylic acid can serve as a precursor for certain esterification and salt-form derivatives, although modification potential in tableted form remains limited by excipient compatibility and regulatory acceptance.
Long-term storage depends on tight controls against moisture and heat. Tablets require cool, dry conditions, with protected packaging to avoid hydrolysis and caking. Exposure to light generally shows minimal effect, although transparent containers are rarely used. If oxygen exposure is a risk, nitrogen blanketing supports long shelf stability in bulk.
Packaging materials must minimize moisture ingress and chemical leachables. Glass and pharmaceutical-grade polymers such as HDPE, PVC, or PVDC are qualified based on chemical resistance and barrier properties. Container compatibility testing addresses migration risk and product reactivity.
Shelf life reflects cumulative exposure to humidity and heat—from production through distribution. Decomposition appears as vinegar-like odor (acetic acid), increased salicylic acid content, tablet sticking, or crumbling. Expiry is established by ongoing stability studies, with periodic analysis required for bulk and finished dosage forms.
GHS labeling recognizes acetylsalicylic acid as a substance with health hazard potential, with emphasis on systemic toxicity and irritant properties. Risk phrases may cover routes of exposure and specific health cautions, depending on product grade and downstream handling.
Handling precautions reflect the irritant and sensitization potential of large quantities and dust exposures. Operator training, gloves, and dust masks are basic controls in manufacturing. Spill control and waste handling follow environmental protection and occupational hygiene standards.
Toxicological profile is characterized by the intended therapeutic dose margin, with acute and chronic toxicity understood from clinical literature. For industrial exposure, key endpoints include respiratory, dermal, and eye irritation, with chronic exposure risks minimized by manufacturing controls.
Occupational exposure standards depend on local jurisdiction. Production staff follow site-specific procedures for personal protective equipment, engineering controls, and environmental monitoring, responding to in-plant air and surface sampling data to drive process improvement and risk mitigation.
Current production volume for Aspirin Tablets depends on installed tablet press lines, upstream supply of pharmaceutical-grade acetylsalicylic acid, and blister or bulk tablet packaging capacity. Capacity expansions in recent years stem from process debottlenecking, line automation, and supplier qualification initiatives. Surge demand from public health events or regulatory policy changes may temporarily draw down available inventory. Output allocation prioritizes long-term institutional supply agreements with pharmaceutical distributors and hospital tender purchases. Periodic maintenance outages, government audits, and GMP revalidation can influence monthly finished product output.
Lead time for standard Aspirin Tablet shipments reflects production queue status, lot release lag, and finished goods logistics scheduling. Smaller lot sizes or custom-packaged SKUs require additional time for changeover and quality review. Typical MOQ aligns with packaging batch minimums and cost breakpoints for pharmaceutical secondary packaging—this is closely related to compliance with national code print requirements and tamper-evident features. Repacking into hospital unit dose blisters, for example, impacts both MOQ and lead time compared to bulk export cartons.
Bulk export cartons utilize heat-sealed poly-liners inside fiberboard for international shipping compliance. Blister packs for hospital and pharmacy distribution follow regional child-resistance norms and serialization mandates. Clinical trial and reference standard packs offer lower count, traceable labeling but involve higher per-tablet cost. Moisture barrier selection and desiccant inclusion relate to regional climatic risk, risk of degradation, and shelf life studies.
Export shipping primarily relies on palletized container freight with validated temperature/humidity control settings when specified by the customer. Commercial terms use EXW, FOB, or CIF based on customer requirement and risk tolerance; air shipment is available for urgent replenishments but subject to prior approval for hazardous goods declaration in some jurisdictions. Payment terms reflect buyer credit risk assessment and may include advance payment, letters of credit, or net terms post-audit. Document legalization and export permit processing times can vary.
Aspirin Tablet cost structure starts with pharmaceutical-grade acetylsalicylic acid, which tracks with the pricing of phenol and acetic anhydride derivatives in upstream chemical markets. Excipient selection (lactose monohydrate, microcrystalline cellulose, starches) and coating agents influence ingredient cost profile, especially for sugar-free or enteric-coated versions. Blister material prices—particularly for aluminum foils and medical-grade plastics—start reflecting energy and supply chain volatility as raw cost drivers.
Significant fluctuations often originate from upstream chemical feedstock supply interruptions (refinery outages, force majeure by key phenol/acetic acid suppliers, trade restrictions). Environmental compliance for parent chemical facilities and regional regulatory crackdowns on emissions may constrict upstream supply, sending cost increases downstream to finished formulation. BSE/MAD cow disease outbreaks have historically impacted gelatin sourcing, affecting encapsulated tablet formulations.
Price difference across SKUs reflects manufacturing complexity for film-coated or enteric-coated grades, enhanced impurity profile, and regulatory dossier requirements in key export markets. Certifications such as EU GMP, US FDA DMF, or WHO PQP status add compliance costs but open higher value tender markets, justifying graded price uplift. Differences in primary packaging—unit dose versus bulk, serialized shipper configurations—directly contribute to total delivered cost.
Global demand follows population growth and aging trends, healthcare access expansion, and periodic spikes linked to public health advisories or stockpiling during pandemic events. Supply concentration remains high; key producer regions (China, India, parts of Europe) control majority output. Capacity investments and regulatory upgrades in ASEAN and Eastern Europe are starting to diversify supply. Downstream branded and generic finished dose supply is tied to regulatory approvals portfolio by pharmaceutical groups.
The United States market places high value on compliance, serialization, and insurance approval; pricing aligns with Medicare/Medicaid tender results. The European Union operates under harmonized quality rules but faces inter-country parallel trade price compression. Japanese procurement standards emphasize particle size, traceability, and uniformity, with strict adherence to pharmacopoeial monographs. Indian and Chinese domestic consumption is large, driving local scale but pricing faces distorting effects from state procurement and bulk tendering.
2026 price forecasts weigh ongoing supply chain disruptions in excipient and blister packaging, potential raw material input cost resets, and the rate of regulatory harmonization in major tender markets. Digital serialization and traceability requirements will continue to add complexity. Regulatory initiatives on nitrosamine impurity control and stricter API traceability in key economies may contribute to incremental compliance costs, driving gradual upward price pressure across bulk and retail markets unless countered by process cost innovations.
Market analysis references up-to-date contract pricing data from registered pharmaceutical trading desks, official customs clearance statistics, supplier and trade association bulletins, ICH and PIC/S regulatory submissions, and raw chemical market tracking agencies. Price movement modeling uses weighted average transaction pricing, mapped to grade segment and packaging format for cross-country comparability.
Capacity expansion projects in India and China over the past two years have focused on cleanroom upgrades, digital batch traceability, and in-process impurity monitoring. Packaging lines have transitioned toward child-resistant formats in response to new safety benchmarks. Several multinationals have shifted from centralized to regionalized blister packing to reduce shipment risk and improve demand response.
Both EU and US agencies have tightened oversight on nitrosamine/NDMA risk management in finished dose products, increasing documentation requirements and analytical workload during batch release. Recent adoption of traceability protocols for high-volume OTC drugs is driving investment in digital packaging technologies and supply chain integration with downstream distributors.
As a manufacturer, response to raw material price pressure includes renegotiating long-term supply contracts, dual sourcing key ingredients, and qualifying local suppliers for excipients and blister films. Continuous improvement projects target lower changeover loss, in-process control automation, and upskilled quality control. Engagement in industry consortia ensures up-to-date compliance with fast-evolving documentation and serialization demands, minimizing regulatory batch release delay.
Aspirin Tablets are produced with diverse industry requirements in mind. Pharmaceutical applications remain the core sector, but formulations for veterinary medicine and research settings also come into play. Each sector operates under its own technical and regulatory environment. Pharmaceutical-grade tablets require validated active pharmaceutical ingredient (API) provenance, compliance with pharmacopoeial standards, and verification of finished product quality through multiple analytical stages. Veterinary formulations can differ in excipient tolerance, impurity profiles, and allowable performance attributes. Research applications prioritize purity, traceability, and batch consistency without always demanding formal regulatory labeling.
| Grade | Application Sector | Key Considerations |
|---|---|---|
| Pharmaceutical Grade | Human and Veterinary Medicine | Regulated API content, compliance with compendia (USP/EP/JP as requested), low allowable impurity levels, prescribed excipient use, validated analytical controls |
| Veterinary Grade | Animal Health | API requirement based on target species, wider excipient compatibility, impurity guidelines aligned with local authorities or pharmacopeia |
| Analytical/Research Grade | Laboratory and R&D | High API purity, batch traceability, documentation for non-clinical use, possible modification in excipient system to aid chemical testing or method development |
Pharmaceutical applications scrutinize assay range, impurity identity and thresholds, tablet hardness, and dissolution attributes, as well as microbiological integrity. Veterinary and research customers pursue batch-to-batch reproducibility but may set different priorities such as alternate packaging, excipient modifications or country-specific testing protocols.
Moisture sensitivity strongly impacts storage and stability. For pharmaceutical grades, desiccant-packed, foil-laminated, or blister packaging is typical to control degradation. Lower-grade products may permit bulk packaging for reduced material handling costs, but this brings higher risk for hydrolysis or exposure-based degradation.
Raw material selection for all applications demands a controlled source of salicylic acid and acetic anhydride. Pharmaceutical grade mandates full traceability, supplier qualification, and compliance with banned impurity lists. Veterinary and research customers may accept variance in minor excipient sources, provided API control is maintained.
Evaluate whether the intended use involves human pharmaceutical, animal health, or research. Each outcome will drive downstream compliance, analytical, packaging, and documentation requirements.
Determine region and end-use regulatory framework. Pharmaceutical applications follow compendial monographs and require robust regulatory submission support. Veterinary and research sectors often operate under a different risk profile but should not assume absence of oversight.
Establish required API assay, impurity specification, and need for low-level contaminant monitoring. Pharmaceutical and critical research applications set narrow impurity ranges and demand confirmation by chromatographic analysis on every batch; other users may select a lower grade to balance purity with cost.
Volume requirements inform packaging options, batch size selection, and even process route. Lower demand volumes may be met through campaign manufacturing and special packaging formats, whereas continual supply at high quantities pushes batch standardization and automation.
Engage the manufacturer for sample tablets from current production. A real-world validation – including dissolution, assay, impurity, and form-factor assessment – supports conclusive grade selection for the user's actual formulation, downstream integration, or R&D protocol. For regulated sectors, batch documentation and certificates of analysis supplement this technical review.
Quality is not asserted through slogans; it is demonstrated in daily operations and batch records. Our production site maintains a quality management system that meets internationally recognized accreditation standards. All certification processes include site inspections and independent audits focusing on reproducibility of processes, traceability from raw material sourcing to finished product dispatch, and precise record-keeping throughout each step of manufacturing. Remedies, corrective actions, and preventive measures address any findings. Ongoing training cycles target systematic gaps to support alignment with evolving pharmaceutical quality standards.
Aspirin tablet grades destined for regulated markets undergo targeted product certification audits, including review of active ingredient identity, dissolution characteristics specific to tablet strength, and uniformity derived from validated mixing and compression steps. Regulatory files include full manufacturing dossiers, cross-checked by both internal and external compliance experts. For each grade, we control excipient batch records, blending protocols, and analytical test data to ensure proper documentation for pharmacopoeial conformity. Final release always references the precise requirements stated by customer or local authority, rather than relying on generic industry parameters.
Comprehensive product documentation includes batch manufacturing records, certificates of analysis (COA), and specification sheets for each customer order. The documentation catalog reflects historical batch data, full analytical profiles, stability testing as applicable by grade, and details for raw material provenance. Auditors and qualified customers may review archived process deviation logs and in-process testing results. Product recalls, deviations, and adverse event reports, when applicable, are tracked with corrective and preventive action summaries to ensure transparency and compliance above market minimums.
Meeting supply commitments relies on dedicated tablet press lines and controlled environmental zones, with core capacity calculated for steady output beyond contractual minimums. Long-term supply agreements secure priority for recurring buyers, while production batch sizes adjust according to real-time order flow and on-hand raw materials. Safety stocks buffer seasonal demand shifts. For buyers with variable requirements, we accommodate volume fluctuations through rolling forecasts and schedule coordination, enabling synchronized shipments and reduced storage risk.
Each manufacturing line is evaluated monthly to maintain core operational capacity targets for aspirin tablets. Process bottlenecks are identified through regular line audits, and critical spares inventory is maintained to minimize downtime. Maintenance scheduling is designed to avoid production gaps. Backup raw material vendors and substitute excipients are pre-qualified to ensure production continuity. When customer orders call for tighter grade control or unique formulation demands, capacity allocation reflects those requirements and is communicated with adequate lead time.
Sample requests begin with a clear statement of intended use and product grade. Technical staff engage directly with prospective buyers to assess compatibility between intended dosage form, local regulatory expectations, and our recommended grade. Representative batch samples are prepared to match the specific compression, coating, or dissolution characteristics needed by the receiving formulation lab. Robust record-keeping for all outgoing samples ensures feedback integration into ongoing manufacturing optimization.
Flexibility in cooperation extends to pricing models, shipment batch sizes, and delivery calendar arrangements. For projects requiring phased rollouts, we offer stepwise release schedules, with each shipment tracked against a master production plan. Buyers seeking confidential development or pilot-scale supply gain the option to isolate their batches in dedicated facilities, subject to additional oversight and reporting requirements. Frequent communication with procurement teams allows rapid response to specification adjustments, regulatory changes, or special audit requests, preserving business continuity and maintaining finished product traceability at all times.
Technical teams devote increasing attention to alternative synthesis routes for aspirin tablets in response to regulatory focus on impurity control. Current development work concentrates on solvent recovery systems, residue minimization, and the reduction of salicylic acid and heavy metal impurities. Production urgency aligns with updated pharmacopoeia standards, driving lab and pilot scale experiments in process purification efficiency.
Process analytical technology is evolving to shorten in-process checks, mainly focusing on endpoint determination in acetylation and drying. R&D groups address direct compression versus wet granulation and assess the impact of excipient selection on tablet durability, dissolution reproducibility, and stability under stress testing conditions.
Medical professionals increasingly investigate aspirin as a component of multi-drug cardiovascular regimens and as an adjunct in protocols for secondary stroke prevention. Combination formulations — particularly with proton pump inhibitors — present formulation and stability challenges. Technical discussions increasingly address patient compliance via sustained release tablet designs and taste-masking for special populations.
Batch-to-batch consistency remains a focus, especially where grade requirements differ for export markets. Technologists invest resources in granulation uniformity, managing acetyl group hydrolysis, controlling bioburden, and managing excipient-aspirin compatibility. Sudden regulatory updates concerning nitrosamine impurities and elemental impurities require prompt method validation revisions.
Technology groups report breakthroughs in inline monitoring and rapid release analytics, supporting real-time quality assurance without stopping a manufacturing line. Upstream, raw material traceability — particularly for acetic anhydride and salicylic acid — requires collaboration with vetted suppliers and vigilant documentation.
Demand for generic aspirin tablets shows moderate growth in both established and emerging markets. Regulatory agencies persistently tighten limits on process impurities and call for transparent environmental-impact reporting during audits. Growth surges appear in value-added formulations, such as enteric-coated and effervescent tablets, especially where pricing aligns with healthcare system reimbursement criteria. Competitive differentiation increasingly depends on consistently low impurity profiles and documentation on residual solvent management.
Process automation and advanced data collection systems increasingly define manufacturing upgrades. Real-time release concepts replace end-point testing for certain critical quality attributes. Excipients with improved functional stability enter the supply chain, but require evaluation for impact on dissolution and bioavailability. Suppliers coordinate on digital batch recordkeeping and controlled integration between raw material sourcing and finished batch release.
Technical and production managers scrutinize solvent and water consumption across the synthesis and tableting stages. Initiatives focus on reducing acetic anhydride and solvent residues in waste, plus implementing higher-yield, lower-waste acetylation chemistries. Process changes sometimes require re-baselining of cleaning validation and updated environmental permit documentation. Teams monitor metrics on effluent load, packaging material origin, and energy consumption. Sustainability compliance increasingly influences purchasing decisions from large healthcare procurement groups.
Technical service teams assist partners with root-cause analysis in cases of tablet friability, capping, non-uniform dissolution profiles, and off-odor development. Support often includes material compatibility checks, formulation troubleshooting, and guidance on in-plant process adjustments. These services alter based on customer region, regulatory requirements, and plant infrastructure.
Manufacturing support teams often recommend process condition modifications based on observed mixing efficiency, compression force feedback, and moisture control outcomes in customer-scale trials. Recommendations for alternative excipient suppliers or granulation processes are tailored to the specific tablet grade and intended medical market. Training is provided for in-line monitoring tools and new analytical validation methods.
Commitments include batch-release documentation, change control notifications, and technical bulletins on updated regulatory and quality control expectations. Dedicated technical liaisons respond to both technical and documentation support queries. Service levels follow mutually agreed technical agreements, with escalation procedures available for urgent production-impacting concerns.
Decades of expertise in chemical synthesis and tableting allow us to produce aspirin tablets at commercial volumes for B2B clients worldwide. Each production batch is managed at our integrated facility, giving us direct oversight of every step—starting from raw material validation, through synthesis and granulation, to the final tablet pressing and coating.
Our aspirin tablets meet the needs of formulation plants, OEM supplement packers, contract manufacturers, and institutional buyers. Pharmaceutical companies use our tablets as ready-to-pack dosage forms, research labs utilize them for test protocols, and contract assemblers integrate them into product kits and multi-dose packaging projects.
Tablet production takes place under validated process controls, with defined parameters for mixing, granulation, drying, and compression. Each lot undergoes laboratory analysis for active content, disintegration, dissolution, and microbiological safety. Results are archived and matched against strict in-house standards. Deviations trigger investigation, so clients receive reliable, specification-matched tablets every time.
Volume packaging options include high-barrier drums, HDPE bottles, and bulk foil pouches, offering protection from moisture and light. Automatic counting and filling lines handle high throughput, matching requirements for sealed bulk or private-label branding. On-site warehousing and logistics systems enable us to load full-containers and LCL shipments on flexible schedules, reducing lead times for industrial procurement planners.
Our technical team works closely with industrial clients during formulation transfer, qualifying trials, and ongoing supply schedules. Specifications can be adjusted to match downstream processing needs, enabling smooth performance in blending, high-speed filling, or kit assembly. Assistance covers qualifying samples, batch documentation, and compliance with regulatory filing requirements for B2B buyers operating across borders.
By managing all aspects of aspirin tablet production in one facility, we deliver cost stability and predictable supply chain performance for distributors and contract assemblers. Direct factory supply minimizes batch-to-batch variability, simplifies compliance audits, and reduces the risk of logistics disruptions. Structured scale-up plans support expansion projects, and process documentation helps our partners meet internal and external quality demands.
| Feature | Industrial Benefit |
|---|---|
| Integrated production line control | Consistent product standards and reliable specification matching |
| Batch-tested and archived results | Quality assurance traceability for audits and regulatory needs |
| Flexible packaging choices | Supports bulk delivery, re-pack projects, and private label lines |
| High-capacity warehousing and shipping | Scalable order fulfillment and reduced shipment wait times |
| Technical guidance for buyers | Problem-solving support during qualification and regular supply |
As direct producers, we support global partners with aspirin tablet supplies that meet the specific requirements of industrial and pharmaceutical operations. Our control of every stage in the supply chain distinguishes our service, providing peace of mind to clients who depend on credible, transparent production for their own market success.
Every aspirin tablet that leaves our production line carries a clear and dependable guarantee for its active ingredient concentration. Our team maintains consistent control over the precise content of acetylsalicylic acid, because end users, pharmacists, clinics, and brands rely on accuracy in dosage with each batch.
In pharmaceutical manufacturing, reliability does not come by chance—it’s an outcome of vigilant adherence to formulation and in-line testing. The well-known standard for aspirin tablets in global markets is 325 mg of acetylsalicylic acid (ASA) per tablet for regular strength and 81 mg per tablet for low dose. Both versions remain widely requested and produced at scale.
No shortcuts can be tolerated. Our technical and operations staff monitor every stage, from raw material input to tableting and packaging. Each batch is subject to rigorous assay and quality control. Typical formulation begins with high-purity ASA, which undergoes blending, granulation, compression, and film coating. The process incorporates checks at critical points—especially after granulation and before compression—so each tablet matches the approved dose specification.
The performance of an aspirin product relies directly on its active content per tablet. Insufficient or excess ASA not only erodes consumer trust but also introduces health risks. Since this medication can impact blood clotting and gastric mucosa, every milligram matters—especially for patients with cardiovascular conditions or aspirin sensitivity. Overdose and underdose both cause clinical consequences. For this reason, accuracy is non-negotiable from a manufacturer’s standpoint.
Our analytical lab uses validated high-performance liquid chromatography (HPLC) methods to verify finished product content—looking for content uniformity and absence of degradation products. Active ingredient levels must stay within established pharmacopeial limits (usually ±5% of label claim), which ensures consistent efficacy and safety. Batch certificates of analysis document every release, and customers have full transparency about product history and compliance.
Maintaining this standard requires investment—not only in equipment, but skilled staff and robust quality management. Every line operator and chemist trains specifically for in-process troubleshooting and preventive measures. For example, humidity or blending inconsistencies can lead to tablet weight variation, which would affect ASA content. Our teams apply regular in-process sampling, real-time feedback, and corrective actions to keep variation tightly controlled.
We also hear frequently from major pharmaceutic buyers and regulatory inspectors about the importance of lot traceability and batch-to-batch consistency for aspirin. The feedback underscores that precision in API concentration is not a selling point but an expectation. Fulfilling that expectation protects both customer health and business reputation.
Whether the requirement is for bulk shipment to formulators or for packaged goods ready for commercial distribution, our technical support staff stands ready to provide documentation and answer any detailed technical queries. Detailed COAs, batch production records, and storage guidance are supplied with each order.
In short, the active ingredient concentration per tablet forms the foundation of our aspirin product. The entire manufacturing system—raw material sourcing, process control, technical validation, and certified release—aims to guarantee that listed ASA content matches what is delivered to customers and users every time.
Producing aspirin tablets at scale involves a balance between process efficiency and quality control. Every batch of tablets passes through precise formulation, tableting, coating, and thorough inspection steps before shipping. In our operations, minimum order quantity ties closely to these production realities. For coated aspirin tablets, the baseline production run makes economic and technical sense at the equivalent of a full batch load, as smaller runs do not take full advantage of our optimized automated tableting and packaging equipment. For most commercial customers, this minimum starts at 100,000 tablets.
Our experience shows that this scale fits typical business needs for pharmaceutical distributors, hospitals, contract packagers, and national pharmacy chains. Producing at smaller scales often increases cost per unit and creates inefficiencies in raw material handling. By maintaining a solid minimum, we streamline quality testing and ensure every order meets strict documentation, including batch records, out-of-spec investigation logs, and retained samples for later trace analysis.
Lead time for standard aspirin tablets usually falls in the 3 to 5 week range, measured from order confirmation to shipment from our plant. The factors impacting lead time include availability of pharmaceutical-grade raw materials, production slot scheduling in our GMP facilities, and final product testing. Since each batch must pass comprehensive QC checks—including potency, dissolution, tablet hardness, friability, and microbial contamination—allocation of adequate testing time is built into our planning. Rush orders can sometimes shift, especially with sudden changes to packaging artwork or regulatory labeling: longer lead times may arise if a client needs particular bottle sizes, blister strips, or printed cartons with custom branding. For our regular contract clients with established order patterns and fixed packaging specs, our technical and logistics teams often secure materials ahead of time, so replenishment timelines shorten to as little as 2 weeks.
One of the most common causes of production delay involves changes to raw material specification or where a client requests additional analytical validation. In those cases, our technical team responds quickly to clarify expectations and deliver the test data needed for customer audits or regulatory reviews. Our documentation and retention system lets us furnish batch certificates of analysis, full traceability for all incoming materials, and all test data for release batches on request.
The minimum order and lead time policies help us balance client needs with our in-house quality commitment and regulatory compliance. By manufacturing in controlled, high-capacity environments, we maintain product consistency batch after batch. We invest continuously in automation, personnel training, and digital tracking to avoid downtime or shipment deviations.
For projects that require alternative dosages, excipients, or packaging formats beyond our standard aspirin tablets, our R&D and production planning teams are ready to review and develop tailored schedules, always rooted in the same principle of reliable production scale. Meeting the quality and delivery expectations set by regulators and our customers starts with thorough planning, up-to-date equipment, and transparent communication on what is possible from a true manufacturing partner.
As the manufacturer, we pay close attention to the evolving regulatory landscape that shapes every aspect of pharmaceutical transport and storage. Aspirin tablets are more than a product—they are a commitment to patient safety, regulatory integrity, and the expectations of regional health authorities. Our compliance approach begins long before the tablets leave our facility.
We design our packaging to withstand the rigors of international transit and local handling. Our packaging lines seal tablets in high-barrier materials, cutting down on the risks of moisture ingress and physical damage. Cartons and shipping cases meet or exceed the impact and crush tests set by many pharmaceutical regulators worldwide.
Every batch receives an individual batch number and an expiry date, both printed with tamper-evident ink. Serialization delivers traceability from our filling line to the end user. These features exist because regulatory bodies—including those with the toughest standards—expect full traceability for every movement of medicine.
We implement stability protocols for aspirin tablets. Our data comes from controlled storage studies at various temperature and humidity settings. We ship only in robust secondary packaging that insulates against temperature spikes, relying on cold chain methods as required by local or shipment-specific guidelines. Data loggers are available for critical shipments. These monitor and record environmental parameters in real time throughout transit.
We consult pharmacopeial standards, such as those published in the destination market, and cross-reference their requirements in our logistics procedures. Consistent ambient storage is essential for tablets—exposure to excessive heat or humidity not only triggers product degradation but also breaches local pharmaceutical law. All warehouses and transit hubs in our distribution network follow established handling protocols, with periodic audits to confirm strict adherence.
We maintain a comprehensive document trail for each shipment. Certificates of Analysis accompany every consignment, along with manufacturing and expiry dates, storage advisories, and any specific transport instructions mandated by the receiving country. Our staff dedicate time to reviewing updated regulatory lists and ensure all batch records reflect the standards enforced by authorities such as the US FDA, European Medicines Agency, Japanese PMDA, and others.
We provide access to inspection reports and analytical data as part of the process—regulators in many countries check these documents at the border to verify compliance with their national product registration.
Our technical team monitors feedback from local distribution agents and healthcare partners. Where transit routes or temperature profiles create challenges, we evaluate solutions such as stronger insulation, faster clearance, or updates to shipping practice. We respond directly to regulatory audits and adapt our methods in response to any finding, no matter how small.
Compliance is not an afterthought. It sits at the core of every delivery we make, and we apply the same standards to domestic and export shipments. Our customers can expect that our aspirin tablets arrive protected, fully documented, and in line with every regulatory requirement at their destination.
For product inquiries, sample requests, quotations or after-sales support, please feel free to contact me directly via sales3@ascent-chem.com, +8615365186327 or WhatsApp: +8615365186327
